Methods using proton pump inhibitors

Abstract

The invention provides methods of treating and preventing asthma, laryngitis, symptomatic gastroesophageal reflux disease, pregnancy-induced gastroesophageal reflux disease, noncardiac chest pains, coughing, apnea, dyspepsia, inflammatory bowel disease, irritable bowel syndrome, gastritis, stress ulcers, bleeding peptic ulcers, acute gastrointestinal bleeding, infectious enteritis, collagenous colitis, lymphocytic colitis, chronic diarrhea in immunocompromised patients, esophageal ulcers in immunocompromised patients, idiopathic gastric acid hypersecretion, gastroparesis, gastrointestinal motility disorders, Zollinger-Ellison syndrome, short bowel syndrome, emesis, regurgitation, early satiety, chronic sore throat, abdominal pain, abdominal bloating, nausea, sour stomach, diarrhea, constipation, bacterial infections, refractory ulcers, gastrointestinal disorders induced by NSAIDs, Barrett's esophagus, gastrointestinal disorders caused by steroids, gastrointestinal disorders induced by cholinergic compounds, and fungal or viral-induced ulcers in the gastrointestinal tract by administering a therapeutically effective amount of at least one proton pump to a patient in need thereof. The invention also provides on demand relief of symptoms associated with gastroesophageal reflux disease (GERD), and provides relief from symptoms caused by the consumption of excessive amounts of food and/or alcohol by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof. The invention also provides methods for treating parasitic infections, such as malaria, by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof.

Description

FIELD OF THE INVENTION The invention provides safe and effective methods for treating and preventing gastrointestinal diseases and other disorders in patients by administering one or more proton pump inhibitors. In preferred embodiments, the proton pump inhibitor is rabeprazole, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. BACKGROUND OF THE INVENTION Duodenal and gastric ulcers, known collectively as peptic ulcers, are localized erosions of the mucous membrane of the duodenum and stomach, respectively, which expose the underlying layers of the gut wall to the acid secretions of the stomach and to the proteolytic enzyme pepsin. They are believed to be caused by an imbalance between offensive factors, such as acid or pepsin, and defensive factors, such as resistance of the mucous membrane. Peptic ulceration is a common disease of the gastrointestinal tract and it is estimated that approximately 10 to 20% of the adult male population will experience peptic u...

AI Technical Summary

Benefits of technology

The invention provides relief from symptoms caused by the consumption of excessive amounts of food and / or alcohol in patients by administering a therapeutically effective amount of at least one proton pump inhibitor. In other embodiments, patients can be administered at least two proton pump inhibitors. In still other embodiments, patients can be administered at least two proton pump inhibitors where at least one of the proton pump inhibitors is rabeprazole, a pharmaceutically acceptable salt thereof and / or a stereoisomer thereof.

Problems solved by technology

They are believed to be caused by an imbalance between offensive factors, such as acid or pepsin, and defensive factors, such as resistance of the mucous membrane.

Images